Odysight.Ai Inc. (ODYS) - Q1 2025 10-Q Summary
Business Context and Reporting Period
Odysight.Ai Inc. is a developer of vision-based platform solutions for Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) markets, utilizing AI and machine learning. The company operates primarily in Israel with subsidiaries in the U.S. and Italy. This report covers the quarterly period ended March 31, 2025. The company began trading on the Nasdaq Capital Market under the symbol "ODYS" on February 11, 2025, following a public offering.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $2.07 million | $0.19 million |
| Gross Profit | $0.54 million | ($0.22 million) Loss |
| Operating Loss | ($4.56 million) | ($3.36 million) |
| Net Loss | ($4.27 million) | ($3.16 million) |
| Cash and Cash Equivalents | $36.88 million | $7.36 million |
| Total Assets | $39.84 million | $23.68 million |
| Total Liabilities | $4.08 million | $5.44 million |
| Backlog (Remaining Performance Obligations) | $14.8 million | $15.0 million (Dec 31, 2024) |
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased by 1,004% year-over-year. This was primarily driven by the derecognition of a contract liability of $1.69 million associated with a Fortune 500 medical customer, as the company no longer expects a 2025 purchase order from this client.
- Cost of Revenue: Increased by 272% to $1.53 million, largely due to the derecognition of a $0.96 million fulfillment asset and a $0.20 million inventory impairment related to the same medical customer.
- Expense Growth: Operating expenses increased significantly due to R&D expansion (59% increase), new executive hires (including a CFO), and costs associated with the Nasdaq uplisting and public offering.
- Liquidity Improvement: Cash balances more than doubled from $18.2 million at year-end 2024 to $37.2 million (including restricted cash) at March 31, 2025, following a February 2025 public offering that raised approximately $20.9 million in net proceeds.
Outlook, Risks, and Management Commentary
- Outlook: Management believes current cash resources will fund operations for at least the next 12 months. The company expects continued investment in R&D and commercialization, with expenses likely to increase before profitability is achieved.
- War in Israel: The ongoing conflict has caused minor disruptions, including employee reserve duty and occasional sheltering, but has not had a material adverse effect on operations to date. Conversely, increased flight hours by the Israeli Air Force have generated growing interest in the company's technology from government agencies.
- Customer Concentration: The company relies on a limited number of customers. The loss of expected revenue from the Fortune 500 medical client in 2025 is a significant factor in current financial adjustments.
- Risks: Key risks include the need for additional financing, dependence on third-party suppliers, regulatory changes, and geopolitical instability in the Middle East.
Investor Verification Checklist
- Medical Customer Status: Verify the finality of the decision regarding the Fortune 500 medical customer and the impact on future revenue streams.
- Burn Rate vs. Cash Runway: Confirm the 12-month liquidity runway given the increased operating expenses and R&D focus.
- Backlog Realization: Assess the convertibility of the $14.8 million backlog into recognized revenue, noting that orders can be cancelled or delayed.
- Geopolitical Exposure: Monitor the impact of the war in Israel on supply chains, employee availability, and international client sentiment.
- Dilution: Review the impact of the recent public offering and outstanding warrants (approx. 5.76 million shares) on future share count and ownership dilution.